MedTrace Logo

Varenicline for Gait and Balance Impairment in Parkinson Disease

NCT01341080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if varenicline is effective in improving gait and balance impairment in patients with Parkinson disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Varenicline

Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.

DRUG

Sugar pill

1mg twice daily for eight weeks after a one week dose escalation phase.

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Deborah A Hall, MD, PhD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-28
Primary Completion
2018-11-02
Completion
2018-11-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341080 on ClinicalTrials.gov